Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Narrow Search
Search narrowed by
Last searches

Results for *

Displaying results 1 to 7 of 7.

  1. Have newer cardiovascular drugs reduced hospitalization?
    Evidence from longitudinal country-level data on 20 OECD countries, 1995 - 2003
    Author: Lichtenberg, Frank R.
    Published: 2008
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    "This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in... more

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (14008)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan

    Location:
    ifo Institut für Wirtschaftsforschung an der Universität München, Bibliothek
    Signature:
    http://www.nber.org/papers/w14008.pdf
    Inter-library loan:
    No inter-library loan

     

    "This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in which it was marketed anywhere in the world. We use annual data on the utilization of over 1100 cardiovascular drugs (active ingredients) in 20 OECD countries during the period 1995-2003. Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of other medical innovations (CT scanners & MRI units), potential risk factors (average consumption of calories, tobacco, and alcohol), and demographic variables (population size & age structure, income, and educational attainment). The estimates also indicate that use of newer cardiovascular drugs has reduced average length of stay and the age-adjusted cardiovascular mortality rate, but not the number of potential years of life lost due to cardiovascular disease before age 70 per 100,000 population. The estimates indicate that if drug vintage had not increased during 1995-2004, hospitalization and mortality would have been higher in 2004. We estimate that per capita expenditure on cardiovascular hospital stays would have been 70% ($89) higher in 2004 had drug vintage not increased during 1995-2004. Per capita expenditure on cardiovascular drugs would have been lower in 2004 had drug vintage not increased during 1995-2004. But our estimate of the increase in expenditure on cardiovascular hospital stays is about 3.7 times as large as our estimate of the reduction in per capita expenditure for cardiovascular drugs that would have occurred ($24)"--National Bureau of Economic Research web site

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 14008
    Subjects: Pharmakologie; Innovation; Herzkrankheit; Krankenhauskosten; Welt
    Scope: 21, [8] S., graph. Darst.
  2. Pharmaceutical innovation and the longevity of Australians
    a first look
    Author: Lichtenberg, Frank R.; Duflos, Gautier
    Published: 2008
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    "We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to the government's Pharmaceutical Benefits Scheme, Australia has much better data on drug utilization than most other countries. ... more

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (14009)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan

    Location:
    ifo Institut für Wirtschaftsforschung an der Universität München, Bibliothek
    Signature:
    http://www.nber.org/papers/w14009.pdf
    Inter-library loan:
    No inter-library loan

     

    "We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to the government's Pharmaceutical Benefits Scheme, Australia has much better data on drug utilization than most other countries. We find that mean age at death increased more for diseases with larger increases in mean drug vintage. The estimates indicate that increasing the mean vintage of drugs by 5 years would increase mean age at death by almost 11 months. The estimates also indicate that using newer drugs reduced the number of years of potential life lost before the ages of 65 and 70 (but not before age 75). During the period 1995-2003, mean age at death increased by about 2.0 years, from 74.4 to 76.4. The estimates imply that, in the absence of any increase in drug vintage, mean age at death would have increased by only 0.7 years. The increase in drug vintage accounts for about 65% of the total increase in mean age at death. We obtain a rough estimate of the cost per life-year gained from using newer drugs. Under our assumptions, using newer drugs (increasing drug vintage) increased life expectancy by 1.23 years and increased lifetime drug expenditure by $12,976; the cost per life-year gained from using newer drugs is $10,585. An estimate made by other investigators of the value of a statistical Australian life-year ($70,618) is 6.7 times as large as our estimate of the cost per life-year gained from using newer drugs. We discuss several reasons why our estimate of the cost per life-year gained from using newer drugs could be too high or too low"--National Bureau of Economic Research web site

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 14009
    Subjects: Pharmakologie; Arzneimittel; Sterblichkeit; Australien
    Scope: 17, [6] S., graph. Darst.
  3. Importation and innovation
    Author: Lichtenberg, Frank R.
    Published: 2006
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (12539)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 12539
    Subjects: Arzneimittel; Import; Preis; Produktqualität; USA; Pharmakologie
    Scope: 18, [7] S., graph. Darst.
    Notes:

    Literaturverz. S. 17 - 18

    Internetausg.: papers.nber.org/papers/w12539.pdf - lizenzpflichtig
  4. Has medical innovation reduced cancer mortality?
    Author: Lichtenberg, Frank R.
    Published: 2010

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (15880)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 15880
    Subjects: Medizin; Pharmakologie; Innovation; Gesundheit; Sterblichkeit; Krebskrankheit; USA
    Scope: 17, [14] S., graph. Darst.
    Notes:

    Parallel als Online-Ausg. erschienen
  5. The effect of pharmaceutical innovation on the functional limitations of elderly Americans
    evidence from the 2004 National Nursing Home Survey
    Author: Lichtenberg, Frank R.
    Published: 2012

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (17750)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 17750
    Subjects: Arzneimittel; Pharmakologie; Ältere Menschen; Pflegeheim; Gesundheit; USA
    Scope: 18, [14] S., graph. Darst.
    Notes:

    Parallel als Online-Ausg. erschienen
  6. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000 - 2009
    Author: Lichtenberg, Frank R.
    Published: 2012

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (18235)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: Working paper series / National Bureau of Economic Research ; 18235
    Subjects: Pharmaindustrie; Pharmakologie; Sterblichkeit; Entwicklungsländer; Industrieländer
    Scope: 22, [8] S., graph. Darst.
    Notes:

    Parallel als Online-Ausg. erschienen
  7. The effect of pharmaceutical innovation on longevity
    patient-level evidence from the 1996-2002 medical expenditure panel survey and linked mortality public-use files
    Author: Lichtenberg, Frank R.
    Published: 2012

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (18552)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 18552
    Subjects: Arzneimittel; Pharmakologie; Sterblichkeit; Gesundheitskosten; USA
    Scope: 23, [13] S., graph. Darst.
    Notes:

    Parallel als Online-Ausg. erschienen